With GOP Control of U.S. House, Expect Increased Oversight of 340B Providers

Screenshot of Twitter post by Kevin McCarthy
U.S. House GOP Leader Kevin McCarthy last night posted this tweet announcing his party will be the majority in the chamber for the next two years.

The Republican Party won control of the U.S. House last evening, securing the requisite 218th seat for majority status after the Associated Press declared Rep. Mike Garcia (R) the winner of a race in California.

Democrats on Nov. 12 won

Read More »

Breaking News

Two of Three Appeals Court Judges Question Government’s Stance That Drug Companies May Not Impose Conditions on 340B Sales

U.S. Third Circuit Court of Appeals court room
Two judges on a three-judge federal appeals court panel in Philadelphia today questioned whether the 340B statute forbids drug manufacturers from imposing distribution conditions on offers of 340B pricing.

Two judges on a three-judge federal appeals court panel this morning challenged a federal government lawyer’s stance that federal law forbids drug manufacturers from limiting how their drugs may be distributed when they offer to sell the drugs at reduced

Read More »

Appeals Court To Hear Arguments Today in AstraZeneca, Novo Nordisk, and Sanofi’s 340B Contract Pharmacy Suits

The seal of the U.S. Third Circuit Court of Appeals
A federal appeals court in Philadelphia is hearing arguments today in AstraZeneca, Novo Nordisk, and Sanofi’s 340B contract pharmacy lawsuits.

A federal appeals court in Philadelphia this morning is hearing arguments in AstraZeneca, Novo Nordisk, and Sanofi’s lawsuits challenging federal agency findings that the drug companies’ 340B contract pharmacy policies are illegal and must stop or the firms could be

Read More »

Hospital Group Says Survey Shows Drug Companies’ 340B Contract Pharmacy Limits Are Harmful

AHA survey depicting hospitals' annualized revenue losses
Drug companies' 340B contract pharmacy limits are harming 340B hospitals and their patients, the AHA says a new member survey shows.

Drug company actions to limit 340B pricing through contract and specialty pharmacies are harming 340B hospitals and their patients, according to a new American Hospital Association member survey.  

AHA released the results yesterday. More than 300 hospitals were surveyed in April,

Read More »

With Democrats Retaining Control of U.S. Senate, Expect New Leadership in Key Committee

Citizen holding I Voted election sticker
Missouri’s 340B contract pharmacy access law has become a hot topic in the state's primary races.

Democrats will still control the U.S. Senate for the next two years, it became clear over the weekend, but control of the House has not yet been decided one week after the Nov. 8 midterm elections.

As of early this

Read More »

Fake Lilly Twitter Account Tweets “Insulin Is Free Now,” Temporarily Wiping Billions From Company’s Stock Value

screenshot of counterfeit Eli Lilly insulin tweet
On Friday, a counterfeit Eli Lilly account bearing a checkmark that caused many to believe the account was authentic tweeted, “We are excited to announce insulin is free now," causing havoc.

The havoc caused by Twitter’s new policy on user identity verification struck drug manufacturer Eli Lilly last week when a counterfeit account bearing one of Twitter’s new $8 checkmarks tweeted, “We are excited to announce insulin is free now.”

The

Read More »

With Party Control of Congress Still Undecided, 340B Providers Lose Some Key Champions but Retain Some Heavy Hitters

Rep. Cathy McMorris Rodgers (R-WA) headshot
Legislation sponsored by Rep. Cathy McMorris Rodgers (R-Wash.) drew a partisan clash at a Sept. 14 hearing over changes it would implement for the 340B program.

Partisan control of Congress for the final two years of President Biden’s term in office was still undecided this morning, two days after Tuesday’s midterm elections.

Major national news organizations say Republicans are favored to take control of the House,

Read More »

MedPAC Is Expected to Make a Policy Recommendation That Could Prompt a Look at 340B Hospital Program Eligibility Criteria

MedPAC wordmark
MedPAC is on track to make a recommendation to Congress that could prompt debate or even action on the 340B program’s use of the Medicare disproportionate share (DSH) patient percentage to determine hospital eligibility.

Congressional Medicare advisers are moving toward recommending what they say is a better way to give extra Medicare funding to safety-net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.

If Congress and the executive branch adopt the proposal, however, it

Read More »

Hospital Groups Ask Court Again to Make CMS Promptly Repay 340B Hospitals for Illegally Withheld Medicare Drug Reimbursement

CMS building
National hospital groups asked a federal judge again to order CMS to promptly repay 340B hospitals for illegally reduced Medicare Part B drug payments from 2018 through late September.

National hospital groups, as expected, late last week asked a judge again to order the federal government to promptly repay 340B hospitals for illegally reduced Medicare Part B drug payments from 2018 through late September. They asked the first time

Read More »

GSK and Purdue Pharma Announce New Rounds of Refunds for 340B Overcharges

screenshot of drug manufacturers 340B refund notices
GlaxoSmithKline and Purdue Pharma announced refunds for overcharging 340B covered entities, GSK for the fourth time and Purdue for the second time this year.

Drug manufacturers GlaxoSmithKline and Purdue Pharma have announced refunds for overcharging 340B covered entities, GSK for the fourth time and Purdue for the second time this year.

The U.S. Health Resources and Services Administration (HRSA) recently posted the companies’ notices

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live